Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer

Fig. 6

Co-mutation of rs104886038 and rs104886035 in DHCR7 reduces its stability and induces its degradation through the ubiquitin–proteasome system. A DHCR7 catalyses the synthesis of cholesterol via both the Bloch and Kandutsch-Russell pathways. B Prediction of the structure of DHCR7. C Amino acid network of DHCR7. D Western blot analysis verified that both wild-type and mutant DHCR7 were overexpressed in sh-DHCR7 GC cells, while the protein expression of mutant DHCR7 was significantly lower than the wild-type. Both wild-type and mutant DHCR7 plasmid were transfected to sh-DHCR7 GC cells. Western blot analysis were performed at 72 h after transfection. E CHX (30 μM) continued to exert effects for 16–24 h, and the level of DHCR7 in the different groups was verified by western blot analysis. F After CHX treatment, WT/MT GC cell lines were treated with CQ (20 μM) and MG132 (10 μM) to verify the degradation pathway of DHCR7. The data are presented as the means ± SDs and calculated by Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page